12 Best Biotech Penny Stocks To Invest In Now

Page 4 of 11

8. Prime Medicine, Inc. (NASDAQ:PRME)

Number of Hedge Fund Investors: 21

Stock Price as of December 26: $2.76

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company pioneering the field of gene editing with its Prime Editing technology. This next-generation technology allows precise and flexible genetic modifications by addressing the root causes of genetic diseases. The company offers transformative therapies for a wide range of inherited conditions by offering one-time therapeutic solutions that have the potential to correct over 90% of known genetic mutations.

Prime Medicine, Inc.’s (NASDAQ:PRME) core technology, Prime Editing, is designed to be modular and versatile, capable of addressing a broad range of genetic conditions across multiple tissues and developmental stages. The company’s lead candidate, PM359, is currently in Phase 1/2 clinical trials for the treatment of chronic granulomatous disease (CGD), a rare genetic disorder that impairs the immune system’s ability to fight off infections. PM359 uses an ex vivo approach, where hematopoietic stem and progenitor cells (HSPCs) are extracted from the patient, genetically modified, and then reinfused into the patient to restore immune function. Clinical data for PM359 is expected in 2025 and will provide critical insights into its efficacy and safety.

Prime Medicine, Inc. (NASDAQ:PRME) is focusing on expanding its pipeline and exploring new therapeutic applications for its Prime Editing platform. One of the company’s key preclinical programs targets Wilson’s disease, a genetic disorder that leads to copper accumulation in the liver. An Investigational New Drug application for this program is scheduled in the first half of 2026.

In addition to these programs, Prime Medicine, Inc. (NASDAQ:PRME) is exploring the use of Prime Editing for other challenging genetic conditions, such as cystic fibrosis (CF), retinitis pigmentosa (RHO adRP), and Friedreich’s Ataxia. The company’s technology can address a variety of genetic errors, from single nucleotide mutations to the elimination of repetitive DNA sequences.

Page 4 of 11